Latest Content

The data in these posters address a central clinical question: can a topical JAK1/JAK2 inhibitor deliver robust efficacy while maintaining a reassuring safety profile?

Jody L. Green, PhD, explains how regulatory decisions shape medication safety amid uptake of OTC drugs.

National data reveal increasing rates of type 1 and type 2 diabetes among children insured through Medicaid and CHIP.

Patients with myasthenia gravis had a more consistent clinical response and fewer deteriorations when using add-on therapy early.

AI-enabled coronary CT angiography reveals total plaque burden beyond calcium scores, improving risk prediction and personalizing cardiovascular prevention.

Socioeconomic adversity in the perinatal period drives widening low birth weight gaps, fueling adverse pregnancy outcomes and deepening maternal and infant health inequities.

Nearly 3 million MA enrollees may lose plan coverage in 2026 as payment reforms drive market exits, hitting rural areas hardest and reshaping competition, explains Mark Meiselbach, PhD.

Investigators in China touted durable responses seen in a phase 2 study of the CAR T-cell therapy relma-cel, which has a similar mechanism of action as liso-cel. At present, there are no approved CAR T-cell therapies for relapsed/refractory mantle cell lymphoma in China.

Environmental factors were a barrier to participation in community activities among people with multiple sclerosis, even after adjusting for personal factors like disease severity.